XETRA - Delayed Quote EUR

Valneva SE (AYJ.DE)

1.8570

-0.0080

(-0.43%)

As of 1:17:26 PM GMT+1. Market Open.

VALNEVA - Declaration of shares and voting rights: November 30, 2024

VALNEVA Declaration of shares and voting rights November 30, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: December 5, 2024 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on which this ch

GlobeNewswire 7 days ago

INRLF

VALN
Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal

Saint-Herblain (France), December 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces the publication of an article on the global health and economic burden of mosquito-borne disease chikungunya in The British Medical Journal (BMJ), one of the world’s leading peer-reviewed medical journals. The article, titled, “The Global Health and Economic Burden of Chikungunya from 2011 to 2020: A Model-Driven Analysis on the Impact of an Emerging Vector-Bor

GlobeNewswire 8 days ago

INRLF

VALN
Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

Antibody levels remained high at 96% seroresponse in line with the two-year persistence data This long-lasting antibody persistence was comparable in older (65+) and younger adults Saint-Herblain (France), December 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive antibody persistence data three years after vaccination with a single dose of its chikungunya vaccine IXCHIQ®. The results are in line with Valneva’s expectations for this va

GlobeNewswire 9 days ago

INRLF

VALN
Chikungunya Vaccine Label Extension Call Likely to Support VALN Stock

The FDA application complements recent label extension submissions to the EMA and Health Canada, highlighting Valneva's strategic push to enhance IXCHIQ's global reach.

Zacks 13 days ago

VLA.PA

GMED

HAE
Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA

To potentially include adolescents and antibody persistence up to two years Saint Herblain (France), November 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the U.S. Food and Drug Administration (FDA) to potentially extend the use of its chikungunya vaccine IXCHIQ®, which is currently approved in adults, to adolescents aged 12 to 17 years. The application also includes adding the two-y

GlobeNewswire 15 days ago

INRLF

VALN
High Growth Tech Stocks To Explore This November 2024

As global markets experience broad-based gains with smaller-cap indexes outperforming large-caps, investors are closely watching the Federal Reserve's upcoming decisions on interest rates amid a strong U.S. labor market and rising home sales. In this environment, identifying high growth tech stocks involves focusing on companies that can capitalize on technological advancements and maintain robust performance despite geopolitical tensions and economic uncertainties.

Simply Wall St. 17 days ago

STRYF

INRLF

VALN
European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

Shares in European vaccine makers tumbled after President-elect Donald Trump picked vaccine sceptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services.

The Wall Street Journal 27 days ago

INRLF

VALN

BVNKF
Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Saint Herblain (France) and Schlieren (Zurich), November 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2b controlled human infection model (CHIM) study of Shigella4V2 (S4V2), the world’s most clinically advanced tetravalent bioconjugate shigellosis vacci

GlobeNewswire 28 days ago

INRLF

VALN
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Saint-Herblain (France), November 12, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at upcoming investor conferences in the United States and Europe. Chief Executive Officer Thomas Lingelbach and Chief Financial Officer Peter Bühler will host moderated “fireside chat” presentations to discuss the Company’s key value drivers and upcoming cat

GlobeNewswire 30 days ago

INRLF

VALN
Valneva SE (INRLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved ...

Valneva SE (INRLF) reports a significant turnaround with increased sales and a positive operating profit, despite challenges in the US market.

GuruFocus.com last month

VLA.PA
Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

Nine-Month Key Financial Highlights Total revenues of €116.6 million, including product sales of €112.5 millionNet Profit of €24.7 million, including proceeds from the Priority Review Voucher (PRV)1 sale Operating profit of €34.2 million compared to an operating loss of €57.2 million in the first nine-months of 2023 Cash position of €156.3 million Includes €61.2 million in gross proceeds from recent private placement2Lower cash burn expected in the second half of 2024 as cost contributions to th

GlobeNewswire last month

INRLF

VALN
VALNEVA - Declaration of shares and voting rights: October 31, 2024

VALNEVA Declaration of shares and voting rights October 31, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: November 6, 2024 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this chang

GlobeNewswire last month

INRLF

VALN
High Growth Tech Stocks in France to Watch October 2024

As the European Central Bank's recent interest rate cuts have buoyed major stock indexes, France's CAC 40 Index has seen a modest increase, reflecting a cautiously optimistic market sentiment amid ongoing monetary easing. In this environment, investors may find it beneficial to focus on high-growth tech stocks that demonstrate strong fundamentals and adaptability in a rapidly evolving economic landscape.

Simply Wall St. last month

INRLF

VALN

OVHFF
Lectra And 2 Other High Growth Tech Stocks In France

As the European Central Bank's recent rate cuts have spurred optimism for further monetary easing, France's CAC 40 Index has seen a modest rise, reflecting broader positive sentiment across major European markets. In this environment of potential economic support and easing inflationary pressures, high-growth tech stocks in France like Lectra are gaining attention for their innovative capabilities and strong market positioning.

Simply Wall St. last month

LCTSF

OVHFF

OVHGY
Exploring 3 High Growth Tech Stocks In France

As the European Central Bank's recent interest rate cuts have buoyed major stock indexes, France's CAC 40 Index has seen a modest rise, reflecting a broader optimism in the region’s economic outlook. In this environment of monetary easing and improved market sentiment, identifying high-growth tech stocks involves looking for companies that can leverage innovation to capitalize on these favorable conditions while demonstrating resilience and adaptability in their business models.

Simply Wall St. last month

VIVHY

VVVNF

INRLF
Valneva to Present on Chikungunya at Several Leading Scientific Conferences

Saint-Herblain (France), October 21, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces today that members of its senior leadership team will present datasets on the world’s first and only approved chikungunya vaccine, IXCHIQ®, at several leading scientific conferences during the fourth quarter of 2024. At the International Society of Vaccines Annual Congress taking place in Seoul, South Korea, Valneva will present on the two-year antibody persistence a

GlobeNewswire last month

INRLF

VALN
High Growth Tech Stocks In France Featuring 3 Promising Companies

Amidst a backdrop of easing monetary policies by the European Central Bank, France's CAC 40 Index has shown modest gains, reflecting a cautiously optimistic sentiment in the broader European market. As investors navigate this evolving landscape, identifying high growth tech stocks becomes essential; these companies often exhibit strong innovation potential and adaptability to changing economic conditions.

Simply Wall St. last month

VIVHY

VVVNF

OVHFF
Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

Saint Herblain (France) and Schlieren (Zurich), October 16, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Shigella4V (S4V), the world’s most clinically advanced tetravalent bioconjugate shigellosis vaccine candidate, for which Va

GlobeNewswire last month

INRLF

VALN
High Growth Tech Stocks In France October 2024

As the French market navigates through a period of heightened caution due to escalating Middle East tensions and broader European economic concerns, the CAC 40 Index has experienced a notable decline. In this environment, identifying high-growth tech stocks in France requires an understanding of companies that can demonstrate resilience and adaptability amidst geopolitical uncertainties and shifting economic landscapes.

Simply Wall St. 2 months ago

INRLF

VALN

GNFT
Valneva Hosts Investor Day in New York City

Live event and webcast TODAY at 10 AM ET Saint Herblain (France), October 10, 2024 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, is hosting an investor day today in New York City to discuss the Company’s key value drivers over the next 12-18 months and beyond. Valneva’s Chief Executive Officer Thomas Lingelbach, Chief Financial Officer Peter Bühler, and other members of the Company’s senior leadership team will highlight the Company’s substantial opportunity for i

GlobeNewswire 2 months ago

INRLF

VALN

Performance Overview

Return	AYJ.DE	CAC 40
YTD	-60.90%	-1.45%
1-Year	-63.02%	-1.56%
3-Year	-91.86%	+6.32%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Valneva SE (AYJ.DE)

VALNEVA - Declaration of shares and voting rights: November 30, 2024

Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal

Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

Chikungunya Vaccine Label Extension Call Likely to Support VALN Stock

Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA

High Growth Tech Stocks To Explore This November 2024

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Valneva SE (INRLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved ...

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

VALNEVA - Declaration of shares and voting rights: October 31, 2024

High Growth Tech Stocks in France to Watch October 2024

Lectra And 2 Other High Growth Tech Stocks In France

Exploring 3 High Growth Tech Stocks In France

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

High Growth Tech Stocks In France Featuring 3 Promising Companies

Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

High Growth Tech Stocks In France October 2024

Valneva Hosts Investor Day in New York City

Performance Overview